EADV 2025 News: New Brivekimig Data Supports Targeting TNF and OX40L in HS
Brivekimig produced clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS), according to new phase 2a data presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France.